UK Markets closed

Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year

  • Oops!
    Something went wrong.
    Please try again later.
·16-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DANVERS, Mass., October 28, 2021--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended September 30, 2021.

Q2 financial summary and operational highlights:

  • Revenue for the quarter totaled $248.1 million, an increase of 18% compared to $209.8 million during the same period of the prior fiscal year.

  • Worldwide Impella® heart pump product revenue for the quarter totaled $235.8 million, an increase of 18% compared to $199.7 million during the same period of the prior fiscal year.

  • U.S. Impella product revenue for the quarter totaled $189.8 million, an increase of 16% compared to $163.2 million during the same period of the prior fiscal year, with U.S. patient usage of Impella heart pumps up 8%.

  • Outside the U.S. Impella product revenue for the quarter totaled $46.0 million, an increase of 26% compared to $36.5 million during the same period of the prior fiscal year. Specifically, Europe product revenue for the quarter totaled $31.3 million, an increase of 28% compared to $24.5 million during the same period of the prior fiscal year. In addition, Japan product revenue for the quarter totaled $11.8 million, an increase of 18% compared to $10 million during the same period of the prior fiscal year.

  • Gross margin for the quarter was 82.3% compared to 81.5% during the same period of the prior fiscal year.

  • Non-GAAP operating income* was $60.4 million, or 24.4% non-GAAP operating margin* for the quarter, compared to $61.3 million non-GAAP operating income,* or 29.2% non-GAAP operating margin* during the same period of the prior fiscal year. GAAP operating income and GAAP operating margin were equal to non-GAAP operating income* and non-GAAP operating margin* for the quarter and the same period of the prior fiscal year, as there were no non-GAAP adjustments in the respective periods.

  • Non-GAAP net income* increased 2% to $47.2 million, or $1.03 per diluted share, compared to non-GAAP net income* of $46.1 million, or $1.01 per diluted share during the same period of the prior fiscal year. GAAP net income for the quarter was $57.0 million, or $1.24 per diluted share compared to GAAP net income of $62.2 million, or $1.36 per diluted share during the same period of the prior fiscal year.

  • The company generated operating cash flows of $60.5 million during the quarter. As of September 30, 2021, the company had $861.5 million of cash and cash equivalents and marketable securities and no debt.

  • On August 18, the company announced that the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed’s Impella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP’s regulatory review processes including design iterations, clinical study protocols and pre-market approval (PMA) application.

"In Q2, we made progress on product innovation and regulatory milestones while leveraging our commercial field team and Abiomed 2.0 Playbook in a challenging environment," said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. "Abiomed remains focused on disciplined execution and sustainable growth as we continue to pursue our goal of becoming the global standard of care for heart pumps that recover hearts and save lives."

FISCAL YEAR 2022 OUTLOOK

Abiomed started the fiscal year with a range of $990 million to $1,030 million with growth of 17% - 22% versus prior year. After a strong Q1 and a solid July, the company upgraded guidance to $1,030 million to $1,050 million with growth of 22% - 24%. Given the delta resurgence and the U.S. hospital labor shortages, the company is updating its fiscal year 2022 revenue guidance and expects revenue to be in the range of $1,010 million to $1,030 million, an increase of 19% to 22%, respectively compared to fiscal year 2021, slightly above the original fiscal year 22 guidance. The company expects its fiscal year 2022 non-GAAP operating margin* to be in the range of 24% - 25%.

*ABOUT NON-GAAP FINANCIAL MEASURES

To supplement its condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the company uses non-GAAP financial measures as described below. The company uses these non-GAAP financial measures for financial and operational decision-making and to evaluate period-to-period comparisons. The company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. The company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the company’s business.

The company uses the following non-GAAP financial measures:

Non-GAAP operating income: The company defines non-GAAP operating income as operating income, excluding the charge for the acquired in-process research and development related to the preCARDIA acquisition.

Non-GAAP operating margin: The company defines non-GAAP operating margin as operating margin, excluding the charge for the acquired in-process research and development related to the preCARDIA acquisition.

Non-GAAP net income and net income per diluted share: The company defines non-GAAP net income and net income per diluted share as net income and net income per diluted share, excluding the charge for the acquired in-process research and development related to the preCARDIA acquisition, the gain recognized on its previously owned minority interest in preCARDIA, the unrealized gain on investment in Shockwave Medical and excess tax benefits associated with stock-based compensation. The company defines non-GAAP EPS as non-GAAP net income divided by non-GAAP diluted shares, which are calculated as GAAP weighted average outstanding shares plus dilutive potential shares outstanding during the period.

Refer to the "Reconciliation of GAAP to Non-GAAP Financial Measures" section of this press release.

The company reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The company believes it is useful to exclude certain items because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods. The company believes that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

EARNINGS CONFERENCE CALL DETAILS

The company will host a conference call to discuss the quarterly results at 8:00 a.m. ET on Thursday, October 28, 2021. The conference call will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd A. Trapp, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via https://edge.media-server.com/mmc/p/ek7gkmtv or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET October 28, 2021 through 11:00 a.m. ET on November 4, 2021. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 5929017.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD STUDY, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System are pending trademarks of Abiomed, Inc.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, future opportunities and expected regulatory approvals and statements in the paragraph under "Fiscal Year 2022 Outlook" section regarding certain business metrics on either or both a GAAP or non-GAAP basis. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "should," "likely," "will" and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the "SEC"), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Abiomed, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share data)

September 30, 2021

March 31, 2021

ASSETS

Current assets:

Cash and cash equivalents

$

241,882

$

232,710

Short-term marketable securities

408,677

350,985

Accounts receivable, net

89,568

97,179

Inventories, net

85,986

81,059

Prepaid expenses and other current assets

45,374

26,032

Total current assets

871,487

787,965

Long-term marketable securities

210,979

264,085

Property and equipment, net

197,184

197,129

Goodwill

78,166

78,568

Other intangibles, net

41,062

42,150

Deferred tax assets

2,975

11,380

Other assets

128,181

113,082

Total assets

$

1,530,034

$

1,494,359

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$

27,621

$

34,842

Accrued expenses

56,744

66,046

Deferred revenues

24,078

24,322

Other current liabilities

5,579

3,759

Total current liabilities

114,022

128,969

Other long-term liabilities

8,303

10,162

Contingent consideration

22,314

24,706

Deferred tax liabilities

832

847

Total liabilities

145,471

164,684

Commitments and contingencies

Stockholders' equity:

Class B Preferred Stock, $.01 par value

Authorized - 1,000,000 shares; Issued and outstanding - none

Common stock, $.01 par value

455

453

Authorized - 100,000,000 shares; Issued 48,197,044 shares as of September 30, 2021 and 47,929,402 shares as of March 31, 2021

Outstanding 45,496,563 shares as of September 30, 2021 and 45,270,948 shares as of March 31, 2021

Additional paid in capital

840,387

800,690

Retained earnings

858,435

828,007

Treasury stock at cost 2,700,481 shares as of September 30, 2021 and 2,658,454 shares as of March 31, 2021

(300,158

)

(288,030

)

Accumulated other comprehensive loss

(14,556

)

(11,445

)

Total stockholders' equity

1,384,563

1,329,675

Total liabilities and stockholders' equity

$

1,530,034

$

1,494,359

Abiomed, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

For the Three Months Ended
September 30,

For the Six Months Ended
September 30,

2021

2020

2021

2020

Revenue

$

248,142

$

209,764

$

500,727

$

374,614

Costs and expenses:

Cost of revenue

43,886

38,736

89,074

74,719

Research and development

41,041

30,525

78,749

56,882

Selling, general and administrative

102,779

79,167

206,263

147,611

Acquired in-process research and development

115,490

187,706

148,428

489,576

279,212

Operating income

60,436

61,336

11,151

95,402

Other income:

Investment income, net

977

1,822

2,027

4,219

Other income, net

5,858

9,757

44,743

34,370

6,835

11,579

46,770

38,589

Income before income taxes

67,271

72,915

57,921

133,991

Income tax provision

10,318

10,702

27,493

27,190

Net income

$

56,953

$

62,213

$

30,428

$

106,801

Net income per share - basic

$

1.25

$

1.38

$

0.67

$

2.37

Weighted average shares outstanding - basic

45,437

45,104

45,374

45,057

Net income per share - diluted

$

1.24

$

1.36

$

0.66

$

2.34

Weighted average shares outstanding - diluted

45,893

45,661

45,857

45,609

Abiomed, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(in thousands, except per share data)

For the Three Months Ended
September 30,

For the Six Months Ended
September 30,

2021

2020

2021

2020

GAAP operating income

$

60,436

$

61,336

$

11,151

$

95,402

Acquired in-process research and development (1)

115,490

Non-GAAP operating income

$

60,436

$

61,336

$

126,641

$

95,402

GAAP operating margin

24.4

%

29.2

%

2.2

%

25.5

%

Non-GAAP operating margin

24.4

%

29.2

%

25.3

%

25.5

%

GAAP net income

56,953

$

62,213

$

30,428

$

106,801

Acquired in-process research and development (1)

115,490

Gain on previously held interest in preCARDIA (2)

(20,980

)

Excess tax benefits on stock-based compensation (3)

(6,171

)

(7,932

)

(9,801

)

(8,454

)

Gain on investment in Shockwave Medical (4)

(3,611

)

(8,167

)

(16,912

)

(26,101

)

Non-GAAP net income

$

47,171

$

46,114

$

98,225

$

72,246

GAAP diluted net income per share

$

1.24

$

1.36

$

0.66

$

2.34

Acquired in-process research and development (1)

2.52

Gain on previously held interest in preCARDIA (2)

(0.46

)

Excess tax benefits on stock-based compensation (3)

(0.13

)

(0.17

)

(0.21

)

(0.19

)

Gain on investment in Shockwave Medical (4)

(0.08

)

(0.18

)

(0.37

)

(0.57

)

Non-GAAP diluted net income per share

$

1.03

$

1.01

$

2.14

$

1.58

GAAP diluted weighted-average shares outstanding

45,893

45,661

45,857

45,609

Non-GAAP diluted weighted-average shares outstanding

45,893

45,661

45,857

45,609

Notes:

(1) In May 2021, the company acquired the remaining interest in preCARDIA for $82.8 million. The company determined that substantially all of the fair value of the acquisition related to the acquired in-process research and development asset, which resulted in accounting for the transaction as an asset acquisition. The fair value of the acquired in-process research and development asset of $115.5 million is primarily comprised of the net consideration paid for the acquired remaining interest of $82.8 million and our previously owned minority interest in preCARDIA of $32.4 million. Since the acquired technology platform is pre-commercial and has not reached technical feasibility as defined by the accounting rules, the cost of the in-process research and development asset was expensed, resulting in a charge of $115.5 million for the six months ended September 30, 2021.

(2) The company recognized a gain of $21 million related to its previously owned minority interest in preCARDIA as described in note (1) above, within the condensed consolidated statement of operations for the six months ended September 30, 2021.

(3) Amount represents the impact of excess tax benefits associated with stock-based compensation in each respective period presented. The company recognized excess tax benefits associated with stock-based compensation of $6.2 million and $7.9 million as an income tax benefit for the three months ended September 30, 2021 and 2020, respectively. The company recognized excess tax benefits associated with stock-based compensation of $9.8 million and $8.5 million as an income tax benefit for the six months ended September 30, 2021 and 2020, respectively.

(4) Amount represents the unrealized gain on investment in Shockwave Medical in each respective period presented. The company recognized an unrealized gain on investment in Shockwave Medical of $4.8 million ($3.6 million, net of tax benefit) and $10.8 million ($8.2 million, net of tax benefit) within other income for the three months ended September 30, 2021 and 2020, respectively. The company recognized an unrealized gain on investment in Shockwave Medical of $22.4 million ($16.9 million, net of tax benefit) and $32.3 million ($26.1 million, net of tax benefit) within other income for the six months ended September 30, 2021 and 2020, respectively.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005326/en/

Contacts

Todd Trapp
Vice President and Chief Financial Officer
978-646-1680
ttrapp@abiomed.com

Tom Langford
Director, Corporate Communications & PR
978-882-8408
tlangford@abiomed.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting